There is good news and bad news when it comes to our understanding of inflammation
in the pathogenesis and treatment of major depressive disorder (MDD). The bad news
is that, like the dexamethasone suppression test or the efficacy of antidepressants
before it, inflammation is oversold as an answer to the mystery of depression and
its treatment. The good news is that an unusually replicable set of findings (for
psychiatry) increasingly paints a consistent picture of the ways in which inflammation
is of value in understanding MDD. In the current issue of Biological Psychiatry, Attwells et al. (
1
) simultaneously extend and confirm what we know already about how brain and body
work together when it comes to inflammation and its role in MDD.
SEE CORRESPONDING ARTICLE ON PAGE 649
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Biological PsychiatryAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Translocator protein distribution volume predicts reduction of symptoms during open-label trial of celecoxib in major depressive disorder.Biol Psychiatry. 2020; 88: 649-656
- Role of inflammation in depression and treatment implications.Handb Exp Pharmacol. 2019; 250: 255-286
- Efficacy and safety of anti-inflammatory agents for the treatment of major depressive disorder: A systematic review and meta-analysis of randomised controlled trials.J Neurol Neurosurg Psychiatry. 2020; 91: 21-32
- Effect of aspirin vs placebo on the prevention of depression in older people: A randomized clinical trial.JAMA Psychiatry Jun 3. 2020; : e201214
- A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: The role of baseline inflammatory biomarkers.JAMA Psychiatry. 2013; 70: 31-41
- Efficacy of adjunctive infliximab vs placebo in the treatment of adults with bipolar I/II depression: A randomized clinical trial.JAMA Psychiatry. 2019; 76: 783-790
- Interleukin (IL)-6: A good kid hanging out with bad friends (and why sauna is good for health).Brain Behav Immun. 2018; 73: 1-2
- Inflammation as a predictive biomarker for response to omega-3 fatty acids in major depressive disorder: A proof-of-concept study.Mol Psychiatry. 2016; 21: 71-79
- Treatment of bipolar depression with minocycline and/or aspirin: An adaptive, 2x2 double-blind, randomized, placebo-controlled, phase IIA clinical trial.Transl Psychiatry. 2018; 8: 27
- Antidepressant activity of anti-cytokine treatment: A systematic review and meta-analysis of clinical trials of chronic inflammatory conditions.Mol Psychiatry. 2018; 23: 335-343
Article info
Publication history
Accepted:
August 5,
2020
Received:
August 1,
2020
Identification
Copyright
© 2020 Published by Elsevier Inc on behalf of Society of Biological Psychiatry.
ScienceDirect
Access this article on ScienceDirectLinked Article
- Translocator Protein Distribution Volume Predicts Reduction of Symptoms During Open-Label Trial of Celecoxib in Major Depressive DisorderBiological PsychiatryVol. 88Issue 8
- PreviewGliosis is common among neuropsychiatric diseases, but the relationship between gliosis and response to therapeutics targeting effects of gliosis is largely unknown. Translocator protein total distribution volume (TSPO VT), measured with positron emission tomography, mainly reflects gliosis in neuropsychiatric disease. Here, the primary objective was to determine whether TSPO VT in the prefrontal cortex (PFC) and anterior cingulate cortex (ACC) predicts reduction of depressive symptoms following open-label celecoxib administration in treatment-resistant major depressive disorder.
- Full-Text
- Preview
